Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2013
10/31/2013WO2013160728A1 Dual targeting compounds for the treatment of alzheimer's disease
10/31/2013WO2013160670A1 Compounds for use as inhibitors of alternative oxidase or cytochrome bc1 complex
10/31/2013WO2013160645A1 Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg
10/31/2013WO2013160492A1 Combination therapy for the treatment of metabolic diseases
10/31/2013WO2013160435A1 Antibacterial quinoline derivatives
10/31/2013WO2013160431A1 Antibacterial quinoline derivatives
10/31/2013WO2013160418A1 Novel compounds
10/31/2013WO2013160396A1 Combination of cd37 antibodies with bendamustine
10/31/2013WO2013160393A1 HIGH COMPLEXITY siRNA POOLS
10/31/2013WO2013160354A1 Crystalline forms of saxagliptin
10/31/2013WO2013160317A2 Crhr1 antagonists for use in the treatment of patients having crh overactivity
10/31/2013WO2013160300A1 Association of beta-glucans and arabinoxylans
10/31/2013WO2013160273A1 (3,4-dichloro-phenyl)-((s)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride and manufacturing processes
10/31/2013WO2013160222A1 Treatment method for steroid responsive dermatoses
10/31/2013WO2013160213A1 Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the use thereof in contraception and gynaecological therapy
10/31/2013WO2013160207A1 Methods for increasing swallowing efficacy
10/31/2013WO2013160200A1 Application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems in the treatment of menorrhagia, as well as intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one for treating uterine bleeding disorders
10/31/2013WO2013159865A1 Use of dicyclohexylmethanol derivatives with anti-microbial properties
10/31/2013WO2013159724A1 4-((substituted phenyl) difluoromethyl) phenoxy carboxylic acid derivative, and preparation method and uses thereof
10/31/2013WO2013159698A1 Fused ring quinazoline hydroximic acid compound and use thereof as anti-tumour drug
10/31/2013WO2013159412A1 Method for extracting and separating ginkgolides
10/31/2013WO2013159411A1 Ginkgolide injection and preparation method thereof
10/31/2013WO2013159226A1 Anti-oxidant properties of cornus sericea
10/31/2013WO2013159225A1 Process for preparation of 17-substituted steroids
10/31/2013WO2013159224A1 2-carbamo(thio)yl-1,3- dioxopropyl derivatives in cancer therapy
10/31/2013WO2013159200A1 Assays, methods and apparatus for assessing rna disruption
10/31/2013WO2013159190A1 Dietary fiber compositions for the treatment of metabolic disease
10/31/2013WO2013159188A1 Polymer-based dialysate
10/31/2013WO2013159166A1 Pharmaceutical oral dosage form for preventing vascular diseases, tablet as pharmaceutical dosage form and gelatin capsule as pharmaceutical dosage form
10/31/2013WO2013159151A1 Combination meloxicam and xylazine therapy in animals
10/31/2013WO2013159140A1 Eds005 skin cancer cream
10/31/2013WO2013134047A3 Aminoquinoline derivatives and uses thereof
10/31/2013WO2013130672A3 Improved cancer treatments and diagnostics
10/31/2013WO2013128379A3 Crystalline polymorphic forms of linagliptin
10/31/2013WO2013128283A3 Inhalable pharmaceutical compositions
10/31/2013WO2013124701A3 Homo- and heterodimeric smac mimetic compounds as apoptosis inducers
10/31/2013WO2013121334A3 Agents for treating neurodegenerative disorders
10/31/2013WO2013120888A3 Core sheath drug delivery devices
10/31/2013WO2013114153A3 Wafer and capsule formulations with enhanced dissolution rates for fenofibrate
10/31/2013WO2013111118A3 Diaziridines for treating neurodegenerative disorders
10/31/2013WO2013111117A3 Diaziridines for treating neurodegenerative disorders
10/31/2013WO2013111066A3 Pharmaceutical compositions containing phosphatidylserine and curcumin
10/31/2013WO2013111014A3 Methods and compositions for treating neuron loss in inflammatory bowel disease
10/31/2013WO2013111013A3 Methods for treating alzheimer's disease by administering certain synthetic compounds
10/31/2013WO2013110744A3 Phragamalin limonoids for the treatment of sexual dysfunction
10/31/2013WO2013108105A3 Novel solvates of darunavir
10/31/2013WO2013105022A3 Rnai agents to treat beta-catenin related diseases
10/31/2013WO2013055899A3 Compositions useful in treating nephropathy and methods for preparation of same
10/31/2013WO2013043085A8 (rs)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide compound which exhibits modulatory activity with a commensurate effect, pharmaceutical substance (variants) and use thereof, composition (variants)
10/31/2013WO2008089439A3 Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
10/31/2013WO2002069885A9 Anti-invasive and anti-angiogenic compositions and methods for treating brain tumors and other diseases
10/31/2013WO2002064559A3 Thrombin inhibitors
10/31/2013US20130291132 Anf-rgc in-gene knock-out animal
10/31/2013US20130289277 Medicament for treating mental and behavioural disorders
10/31/2013US20130289223 Polymeric coupling agents and pharmaceutically-active polymers made therefrom
10/31/2013US20130289131 Injectable pharmaceutical compositions for the treatment of joints
10/31/2013US20130289127 Aminoalkanol derivatives
10/31/2013US20130289126 Cell aging as a unique biomarker of major depression
10/31/2013US20130289121 Pulmonary disease treatment and diagnosis based on arhgef1
10/31/2013US20130289119 Formulation comprising arginine, use and preparation thereof
10/31/2013US20130289116 Epilepsy treatment employing ketogenic compounds which arrest apoptosis (as amended)
10/31/2013US20130289110 Methods and lipid compositions for promoting development of gut flora
10/31/2013US20130289109 Inhibitors of alpha4 mediated cell adhesion
10/31/2013US20130289107 Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
10/31/2013US20130289105 Hepsin inhibitors
10/31/2013US20130289104 Aliphatic amino acid biosynthesis inhibitors and a method of synthesizing the same
10/31/2013US20130289103 Anti-microbial composition
10/31/2013US20130289102 Amyris alcohol and its ester for treating acne
10/31/2013US20130289098 Compositions and methods for treatment of ovarian cancer
10/31/2013US20130289097 Compositions for conferring tolerance to viral disease in social insects, and the use thereof
10/31/2013US20130289095 Synthetic lethality in cancer
10/31/2013US20130289087 Compositions and methods for the treatment of overactive bladder
10/31/2013US20130289084 Combination therapy
10/31/2013US20130289082 Composition and Method for Treating a Neurodegenerative Event
10/31/2013US20130289074 New indanyloxydihydrobenzofuranylacetic acids
10/31/2013US20130289073 Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
10/31/2013US20130289070 Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines
10/31/2013US20130289069 Controlled Delivery System
10/31/2013US20130289068 Enhanced migraine treatments based on ghrelin mimetics
10/31/2013US20130289066 Anti-angiogenic compound
10/31/2013US20130289065 Liquid pharmaceutical formulations of palonosetron
10/31/2013US20130289062 Compositions for deterring abuse of opioid containing dosage forms
10/31/2013US20130289061 Methods and compositions to prevent addiction
10/31/2013US20130289059 Beneficial effects of increasing local blood flow
10/31/2013US20130289058 Cyclic bridgehead ether dgat1 inhibitors
10/31/2013US20130289056 Methods of administering an egfr inhibitor
10/31/2013US20130289053 Depot formulations
10/31/2013US20130289046 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors
10/31/2013US20130289035 Method of treatment of attention deficit/hyperactivity disorder (adhd)
10/31/2013US20130289029 Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist
10/31/2013US20130289027 Isoquinoline Compounds And Methods For Treating HIV
10/31/2013US20130289024 Compositions and methods for treatment of filovirus-mediated diseases
10/31/2013US20130289023 Method for treating brain tumor
10/31/2013US20130289021 Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
10/31/2013US20130289019 Methods of treating behaviorial and/or mental disorders
10/31/2013US20130289018 New Use of Staurosporine Derivatives
10/31/2013US20130289017 5 (1,2,3-triazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidine derivatives
10/31/2013US20130289016 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
10/31/2013US20130289014 Combination therapy in treatment of oncological and fibrotic diseases
10/31/2013US20130289012 1,2,4-oxadiazole and 1,2,4-thiadiazole beta-lactamase inhibitors
1 ... 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 ... 7860